Tract Closure in PCNL

Recruiting now · Not applicable

Conditions studied: Nephrolithiasis

In brief

This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.

Key facts

Study ID

NCT07668817

Run by

Icahn School of Medicine at Mount Sinai

People needed

92

Starts

2026-07-01

Expected to finish

2028-06-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one stone ≥ 1.2cm
• Scheduled to undergo planned PCNL
• Age ≥ 18 years

You may not qualify if…

• Unable to provide informed consent
• Pre-existing nephrostomy tube
• Multi access cases
• Stone in calyceal diverticulum/hydrocalyx
• Preoperatively planned overnight admission for any reason
• Infundibular stenosis
• Coagulation disorders
• Other significant anatomic abnormalities

Where it is running

• Mount Sinai West — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.